🚀 VC round data is live in beta, check it out!
Kanghong Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kanghong Pharmaceutical and similar public comparables like Structure Therapeutics, Aspen Pharmacare, Santen Pharmaceutical, Virbac and more.
Kanghong Pharmaceutical Overview
About Kanghong Pharmaceutical
Chengdu Kanghong Pharmaceutical Group Co Ltd is a pharmaceutical company. The company is engaged in the research and development, production, and sales of medicine, chemical medicine, and biological products.
Founded
1996
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$3B
Kanghong Pharmaceutical Financials
Kanghong Pharmaceutical reported last 12-month revenue of $726M and EBITDA of $259M.
In the same LTM period, Kanghong Pharmaceutical generated $647M in gross profit, $259M in EBITDA, and $187M in net income.
Revenue (LTM)
Kanghong Pharmaceutical P&L
In the most recent fiscal year, Kanghong Pharmaceutical reported revenue of $653M and EBITDA of $221M.
Kanghong Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $726M | XXX | $653M | XXX | XXX | XXX |
| Gross Profit | $647M | XXX | $584M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $259M | XXX | $221M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $187M | XXX | $175M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 27% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kanghong Pharmaceutical Stock Performance
Kanghong Pharmaceutical has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Kanghong Pharmaceutical's stock price is $3.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | -2.5% | XXX | XXX | XXX | $0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKanghong Pharmaceutical Valuation Multiples
Kanghong Pharmaceutical trades at 3.7x EV/Revenue multiple, and 10.3x EV/EBITDA.
EV / Revenue (LTM)
Kanghong Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Kanghong Pharmaceutical has market cap of $4B and EV of $3B.
Equity research analysts estimate Kanghong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kanghong Pharmaceutical has a P/E ratio of 19.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBIT | 12.0x | XXX | 14.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | 4.5x | XXX | XXX | XXX |
| P/E | 19.2x | XXX | 20.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 14.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kanghong Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kanghong Pharmaceutical Margins & Growth Rates
Kanghong Pharmaceutical's revenue in the last 12 month grew by 5%.
Kanghong Pharmaceutical's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kanghong Pharmaceutical's rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kanghong Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 48% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 36% | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kanghong Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kanghong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Structure Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aspen Pharmacare | XXX | XXX | XXX | XXX | XXX | XXX |
| Santen Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Virbac | XXX | XXX | XXX | XXX | XXX | XXX |
| Brightgene Bio-medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kanghong Pharmaceutical M&A Activity
Kanghong Pharmaceutical acquired XXX companies to date.
Last acquisition by Kanghong Pharmaceutical was on XXXXXXXX, XXXXX. Kanghong Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kanghong Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKanghong Pharmaceutical Investment Activity
Kanghong Pharmaceutical invested in XXX companies to date.
Kanghong Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Kanghong Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kanghong Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kanghong Pharmaceutical
| When was Kanghong Pharmaceutical founded? | Kanghong Pharmaceutical was founded in 1996. |
| Where is Kanghong Pharmaceutical headquartered? | Kanghong Pharmaceutical is headquartered in China. |
| Is Kanghong Pharmaceutical publicly listed? | Yes, Kanghong Pharmaceutical is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Kanghong Pharmaceutical? | Kanghong Pharmaceutical trades under 002773 ticker. |
| When did Kanghong Pharmaceutical go public? | Kanghong Pharmaceutical went public in 2015. |
| Who are competitors of Kanghong Pharmaceutical? | Kanghong Pharmaceutical main competitors are Structure Therapeutics, Aspen Pharmacare, Santen Pharmaceutical, Virbac. |
| What is the current market cap of Kanghong Pharmaceutical? | Kanghong Pharmaceutical's current market cap is $4B. |
| What is the current revenue of Kanghong Pharmaceutical? | Kanghong Pharmaceutical's last 12 months revenue is $726M. |
| What is the current revenue growth of Kanghong Pharmaceutical? | Kanghong Pharmaceutical revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Kanghong Pharmaceutical? | Current revenue multiple of Kanghong Pharmaceutical is 3.7x. |
| Is Kanghong Pharmaceutical profitable? | Yes, Kanghong Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kanghong Pharmaceutical? | Kanghong Pharmaceutical's last 12 months EBITDA is $259M. |
| What is Kanghong Pharmaceutical's EBITDA margin? | Kanghong Pharmaceutical's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Kanghong Pharmaceutical? | Current EBITDA multiple of Kanghong Pharmaceutical is 10.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.